Related Experiment Video
Updated: Jun 3, 2026
07:52
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Missing data issues at the FDA Center for Biologics Evaluation and Research
1Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Maryland, USA. John.Scott@fda.hhs.gov
Journal of Biopharmaceutical Statistics
|March 11, 2011
Summary
Missing data in clinical trials complicates regulatory review for drugs and biologics. Addressing these data gaps is crucial for ensuring the integrity of safety and efficacy evaluations by the U.S. Food and Drug Administration.
Area of Science:
- Biostatistics
- Regulatory Science
- Clinical Trial Methodology
Background:
- Missing data present significant challenges in regulatory settings, impacting the U.S. Food and Drug Administration's evaluation of drug, biologic, and device safety and efficacy.
- The integrity of statistical analyses is compromised by missing data, complicating regulatory decision-making with substantial public health, legal, and financial consequences.
Purpose of the Study:
- To review the specific challenges posed by missing data within the Center for Biologics Evaluation and Research (CBER).
- To identify limitations in current methodologies for handling missing data in regulatory submissions.
- To propose potential future directions for improving the management of missing data.
Main Methods:
- Literature review of existing approaches to missing data in regulatory science.
- Analysis of challenges specific to the Center for Biologics Evaluation and Research.
- Discussion of current limitations and future research directions.
Main Results:
- Identified unique missing data challenges encountered by CBER.
- Highlighted deficiencies in current statistical approaches for handling missing data in regulatory contexts.
- Outlined areas for methodological advancement.
Conclusions:
- Current methods for addressing missing data in regulatory submissions require improvement.
- Further research into robust statistical techniques is necessary to enhance the reliability of regulatory decision-making.
- Addressing missing data is critical for public health, legal, and financial integrity in drug and biologic approvals.
More Related Videos
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...